# Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/effect-of-pembrolizumab-plus-neoadjuvant-chemotherapy-on-pathologic-complete/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Rita Nanda,Minetta C. Liu,Christina Yau,Rebecca Shatsky,Lajos Pusztai,Anne M. Wallace,A. Jo Chien,Andres Forero‐Torres,Erin D. Ellis,Heather Han,Amy S. Clark,Kathy S. Albain,Judy C. Boughey,Nora Jaskowiak,Anthony Elias,Claudine Isaacs,Kathleen Kemmer,Teresa Helsten,Melanie Majure,Erica Stringer-Reasor,Catherine Parker,Marie Catherine Lee,Tufia C. Haddad,Ronald Cohen,Smita Asare,Amy Wilson,Gillian L. Hirst,Ruby Singhrao,Katherine Steeg,Adam L. Asare,Jeffrey B. Matthews,Scott Berry,Ashish Sanil,Richard B. Schwab,W. Fraser Symmans,Laura van ‘t Veer,Douglas Yee,Angela DeMichele,Nola M. Hylton,Michelle Melisko,Jane Perlmutter,Hope S. Rugo,Donald A. Berry,Laura J. Esserman |
| Citations | 715 |
| DOI | 10.1001/jamaoncol.2019.6650 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://jamanetwork.com/journals/jamaoncology/articlepdf/2761193/jamaoncology_nanda_2020_oi_190112.pdf |
| OpenAlex ID | https://openalex.org/W3005738019 |
| PMID | 32053137 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Judy C. Boughey](https://scholariq.org/researchers/judy-c-boughey/)
- [A. Jo Chien](https://scholariq.org/researchers/a-jo-chien/)
- [Christina Yau](https://scholariq.org/researchers/christina-yau/)
- [Anne M. Wallace](https://scholariq.org/researchers/anne-m-wallace/)
- [Laura J. Esserman](https://scholariq.org/researchers/laura-j-esserman/)

## Paper journal

- [JAMA Oncology](https://scholariq.org/journals/jama-oncology/)

## Paper primary topic

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

## Paper topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.